Study S002217

REVERsal to Normoglycemia by Treating PREDIABETES: The REVERT-PREDIABETES Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)

Registration

Registration: NCT07392151
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: NOT_YET_RECRUITING
Enrollment: 158
Start: 2026-02
Primary completion: 2029-10
Lead sponsor: Michael Mæng
Conditions: Prediabetes; Chronic Coronary Syndrome
Interventions: DRUG:Intensified medical follow-up and glucose-lowering drugs; OTHER:No intervention
Results posted: FALSE
Secondary identifiers: NIH:2025

Registered primary outcomes

Presence of a composite of retinopathy, nephropathy, neuropathy, and MASLD [Baseline]
Incidence of normoglycemia defined as HbA1c <39 mmol/mol [1-year follow-up]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.